Blood Cancer: Advanced Therapy Medicinal Products
The question
To ask the Secretary of State for Health and Social Care, what steps he plans to take to ensure that the NHS has the (a) ability and (b) resource to roll out (i) CAR-T therapies and (ii) other Advanced Therapy Medicinal Products for blood cancer.
Answered by Karin Smyth
The National Health Service in England is required to fund medicines and treatments recommended by the National Institute for Health and Care Excellence (NICE) as a clinically and cost-effective use of NHS resources. NHS England has undertaken considerable activity to support NICE-recommended CAR-T therapies which are currently commissioned and those that may be available in the future.
There are 3 CAR-T products currently available for four types of blood cancer which have treated over 1,500 people to date: these products were made available via the Cancer Drugs Fund which provides early access to promising new cancer medicines. Two additional CAR-T products are currently being evaluated by NICE.
NHS England uses horizon scanning to see what is coming and has a dedicated team to support the adoption of advanced therapy medicinal products (ATMPs) that are recommended by NICE into the NHS. The team works with a variety of internal and external stakeholders to ensure timely patient access to ATMPs that are on the NICE technology appraisal and highly specialised technology workplan. NHS England regularly engages with clinicians who provide CAR-T therapy in order to ensure that there is sufficient capacity within the service to deliver this.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →